Markus Puhlmann
Chief Medical OfficerDr. Markus Puhlmann, MD, MBA, is Chief Medical Officer of Perspective Therapeutics since February 05, 2023. Dr. Puhlmann serves as a Chief Medical Officer at Viewpoint Molecular Targeting, Inc. since October 2022. Dr. Puhlmann has experience in oncology drug development in solid and liquid tumor indications. Before joining Viewpoint, he was the CD30 Franchise Head of Global Clinical Development, Seagen from 2019 to 2022. Prior to his time at Seagen, Dr. Puhlmann's work as Section Head at Merck & Co led to many successful regulatory filings for pembrolizumab from 2015 to 2019 in various indications for urothelial carcinoma, RCC and cervical cancer. Earlier in his career, he held various positions with increasing responsibilities in clinical development and medical affairs at Schering Plough, Bayer and Amgen. Dr. Puhlmann began his career as an academic physician in Germany, the UK and in the US at the National Cancer Institute (NCI). In addition, Dr. Puhlmann led the clinical development program for the collaboration of the partnership between Merck and EISAI. Earlier in his career, he held various positions with increasing responsibilities in clinical development and medical affairs at Schering Plough, Bayer and Amgen. Dr. Puhlmann also spent six years at the Surgery Branch, NCI, NIH, where he researched suicide gene therapy approaches including the effects of cytokines on tumor neovasculature. Dr. Puhlmann trained as a surgeon in the UK and Germany and holds a medical degree from the Ludwig Maximilians University, Munich, Germany as well as an Executive MBA from Georgetown’s McDonough School of Business.
Positions
- Company NamePerspective Therapeutics, Inc.Stock CodeCATXPositionChief Medical OfficerColleagues
- JMJohan M. SpoorCEO & Director
- LALori A. Holmes-WoodsChairperson of the Board
- JDJoel David SendekCFO & Principal Financial Officer
- MKMichael K. SchultzCo-Founder & Senior Scientific Advisor
- SCShane CobbExecutive Vice President of Operations
- RFRobert Froman WilliamsonIndependent Director
- FMFrank MorichIndependent Director
- HHHeidi HensonIndependent Director
